



Caprion Biosciences to Present “Direct Identification of Neo-epitopes for Cancer Vaccines and Adoptive T-Cell Therapies”

Novel findings to be presented at the 2016 Immuno Oncology 360 on February 2nd
New York Academy of Medicine, New York, NY

Montreal, Canada – February 2, 2016— Caprion announced today that its Vice President of Biomarker Discovery and Diagnostics, Dr. Eustache Paramithiotis, will present data on direct detection of peptides presented by MHC from cancers neo-epitopes in their most physiologically relevant state. These findings to be presented today at the 2016 Immuno Oncology 360 conference in New York, demonstrate how peptides naturally presented to the MHC complex can be characterized using surgically resected renal cell carcinomas. The new method developed using Caprion’s ProteoCarta™ proteomic platform allows for the elution of peptides from MHC complexes present on T cells directly from human tissues, the systematic sequencing of all peptides from this epitope repertoire and the assessment of the frequency at which they are presented. The method paves the way for a more rapid and systematic identification from human tumors of the large repertoire of natural epitopes that can be recognized by T cells to mount an immune response. Such immune response can subsequently be assessed and monitored using Caprion’s ImmuneCarta™ flow cytometry platform.

Martin LeBlanc, President and CEO of Caprion said, “We are excited to showcase our capabilities in the direct detection of peptides presented by the MHC complexes. In addition to their relevance to the development of neo-epitopes enabling novel immuno-vaccines, these findings provide further evidence of Caprion’s ability to deliver innovative therapeutic target and biomarker discovery solutions for our clients.”

Presentation Title: Direct Identification of Neo-epitopes for Cancer Vaccines and Adoptive T-Cell Therapies

Speaker: Eustache Paramithiotis, PhD, Vice President, Biomarker Discovery & Diagnostics

Time: Tuesday February 2nd, 11:00am

About Caprion Biosciences, Inc.

Caprion is the leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its immune monitoring business unit, ImmuneCarta®, offers proprietary multiparametric flow cytometry services for functional analyses of innate and adaptive immune responses. Caprion’s proteomics business unit, ProteoCarta™, offers proprietary gel-free, label-free mass spectrometry (MS) for comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers. Caprion also leverages ProteoCarta and ImmuneCarta to develop its own in-vitro diagnostic products

targeting cancer, metabolic and infectious diseases. Based in Montreal, Canada, Caprion has been providing large-scale proteomics and immune monitoring services to over 50 major pharmaceutical and biotech clients for more than 12 years. Caprion, a privately-held company, is majority owned by Chicago Growth Partners. For more information, please visit www.caprion.com.

Media Contact:

Carol Berry

Chief Business Officer, SVP

Caprion Biosciences

cberry@caprion.com

514.360.3600